

Update Information

December 2006

DDIS

Division of
Drug Information Service

Subscriber Information

2006 CD-ROM (1990-current) disc return procedures: It is not necessary to return your monthly outdated (1990-current) Index Record disc to *IDIS*. After you have checked your new monthly (1990-current) Index Record disc, please destroy the previous month's disc. The Article disc is a permanent file, NEVER DISCARD! Place the disc at the end of your current article disc file in chronological order for easy access.

IDIS WWW Home Page: Iowa Drug Information Service has a Home Page on the WWW linked to the University of Iowa. Copies of the *World of Drug Information* newsletter, FDA Approval Packages and a form to request a CD-ROM or Web trial can be found here. You can also send us an Internet message directly from our Home Page. The address is: <http://www.uiowa.edu/~idis>

IDIS toll-free number: A toll-free number is available to our U.S. subscribers for questions, comments or inquiries. The number is 1-800-525-4347 (1-800-525-*IDIS*). We encourage you to make use of this number.

Retrieval Software Sublicense Agreement (RSSA): It is not necessary for CD-ROM subscribers to sign an RSSA agreement for their 2006 *IDIS* subscription. A copy of the RSSA will be enclosed with each monthly update shipment.

CD-ROM Retrospective Articles: The 1997 - 2005 CD-ROM articles are available for purchase. Please check your 2006 Price Sheet for cost information.



NEW DRUG TERMS

	<u>NUMBER</u>
BELAGENPUMATUCEL-L	10120622
CDB-2914	68320008
FROPENEM	8122946
ICA-17043	92000254
ISIS-301012	14000712
MLN-2704	10120865
NBI-42902	68180909
PALOSURAN	95000309
PAZOPANIB	14000512
PI-88	10120864
SAXAGLIPTIN	68200015
ST-1859	95000308
ZK-253	10100010

DRUG NAME/NUMBER CHANGES

OLD TERM	NUMBER	NEW TERM	NUMBER
ANTI-EGF RECEPTOR MONOCLON AB	82000403	PANITUMUMAB	82000403
ANTI-ID AB CA-125	82000604	ABAGOVOMAB	82000604
CG-8123	80120089	CG-8123	10120623

FDA APPROVAL PACKAGES

Article Numbers 563872-563883: Pramlintide Acetate Injection, Symlin. *FDA Approval Package 2005.*

Article Numbers 563074-563085: Anidulafungin for Injection, Eraxis. *FDA Approval Package 2006.*

Article Numbers 563063-563073: Dasatinib, Sprycel. *FDA Approval Package 2006.*

CONTINUING EDUCATION ARTICLES

Article Number 564608: Gold DT. Medication Adherence: A Challenge for Patients with Postmenopausal Osteoporosis and Other Chronic Illness. (*IDIS* Note: The 2.0 Hours of CE Credit is for All Articles in the Issue, Article Numbers 564606-564608). *J Manag Care Pharm* 2006, 12:S20-S25. (0.2 CEU)

Article Number 564607: O'Connell MB. Prescription Drug Therapies for Prevention and Treatment of Postmenopausal Osteoporosis. (*IDIS* Note: The 2.0 Hours of CE Credit is for All Articles in the Issue, Article Numbers 564606-564608). *J Manag Care Pharm* 2006, 12:S10-S19. (0.2 CEU)

Article Number 564606: Kamel HK. Postmenopausal Osteoporosis: Etiology, Current Diagnostic Strategies, and Nonprescription Interventions. (*IDIS* Note: The 2.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 564606-564608). *J Manag Care Pharm* 2006, 12:S4-S9. (0.2 CEU)

Article Number 564578: Berchou R. Economic and Quality-of-Life Implications of Parkinson Disease and Its Treatment. (*IDIS* Note: The 3.0 Hours of CE Credit is for Article Numbers 564573-564578). *Formulary* 2006, 41:39-44. (0.3 CEU)

Article Number 564577: Hauser RA. Efficacy and Safety of Rasagiline in the Treatment of Parkinson Disease. (*IDIS* Note: The 3.0 Hours of CE Credit is for All Articles in the Issue, Article Numbers 564573-564578). *Formulary* 2006, 41:31-38. (0.3 CEU)

CONTINUING EDUCATION ARTICLES-(CONTINUED)

- Article Number 564576:** Ondo WG. Rasagiline Preclinical Studies: Implications for Neuroprotection. (*IDIS* Note: The 3.0 Hours of CE Credit is for All Articles in the Issue, Article Numbers 564573-564578). *Formulary* 2006, 41:25-30. (0.3 CEU)
- Article Number 564575:** Chen JJ. Pharmacology and Pharmacokinetics of Rasagiline: A Selective, Irreversible, Second-Generation MAO-B Inhibitor. (*IDIS* Note: The 3.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 564573-564578). *Formulary* 2006, 41:18-24 (0.3 CEU)
- Article Number 564574:** Waters CH. Pharmacologic Management of Parkinson Disease: Treatment of Levodopa-Associated 'Wearing Off'. (*IDIS* Note: The 3.0 Hours of CE Credit is for All Articles in the Issue, Article Numbers 564573-564578). *Formulary* 2006, 41:12-17. (0.3 CEU)
- Article Number 564573:** Pahwa R. Pharmacologic Management of Parkinson Disease: Initial Therapy. (*IDIS* Note: The 3.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 564573-564578). *Formulary* 2006, 41:4-11. (0.3 CEU)
- Article Number 564572:** Levien TL. Tight Glycemic Control: Reducing Complications in the Hospitalized Patient. *Hosp Pharm* 2006, 41:1-12. (0.15 CEU)
- Article Number 564556:** Cada DJ, Levien T, Baker DE. Ibandronate Intravenous. *Hosp Pharm* 2006, 41:868-879. (0.15 CEU)
- Article Number 564188:** Blonde L, Rosenstock J, Triplitt C. What are Incretins, and How Will They Influence the Management of Type 2 Diabetes? *J Manag Care Pharm* 2006, 12:S1-S12. (0.15 CEU)
- Article Number 564130:** Marrs JC, Saseen JJ. Chronic Stable Angina: Angiotensin-Converting Enzyme Inhibitor Therapy and/or Calcium-Channel Blocker Therapy--When is it Indicated? *J Pharm Technology* 2006, 22:271-280. (0.1 CEU)
- Article Number 564094:** Anonymous. Antiviral Drugs for Prophylaxis and Treatment of Influenza. (*IDIS* Note: The 1.0 Hour of CE Credit is for Two Articles in the Issue, Article Numbers 564093 and 564094). *Med Lett Drugs Ther* 2006, 48:87-88. (0.1 CEU)
- Article Number 564093:** Anonymous. Ranibizumab (Lucentis) for Macular Degeneration. (*IDIS* Note: The 1.0 Hours of CE Credit is for Two Articles in the Issue, Article Numbers 564093 and 564094). *Med Lett Drugs Ther* 2006, 48:85-86. (0.1 CEU)
- Article Number 564092:** Anonymous. Influenza Vaccine 2006-2007. (*IDIS* Note: The 1.0 Hours of CE Credit is for Article Numbers 562369 and 562370) (Addendum) (Art 562369). *Med Lett Drugs Ther* 2006, 48:85. (0.1 CEU)
- Article Number 564074:** Nies LK, Cymbala AA, Kasten SL, Lamprecht DG, Olson KL. Complementary and Alternative Therapies for the Management of Dyslipidemia. *Ann Pharmacotherapy* 2006, 40:1984-1992. (0.1 CEU)
- Article Number 564073:** Fulco PP, Vora UB, Bearman GML. Acid Suppressive Therapy and the Effects on Protease Inhibitors. *Ann Pharmacotherapy* 2006, 40:1974-1983. (0.1 CEU)
- Article Number 564071:** Dennis VC, Albertson GL. Doxercalciferol Treatment of Secondary Hyperparathyroidism. *Ann Pharmacotherapy* 2006, 40:1955-1965. (0.1 CEU)
- Article Number 563719:** Zabinski RA. Evidence-Based Health Benefits Management: Strategies to Optimize Antiretroviral Medication Adherence and Outcomes in HIV/AIDS. (*IDIS* Note: The 2.0 Hours CE Credit is for All Articles in the Issue, Numbers 563717-563719). *J Manag Care Pharm* 2006, 12:S12-S16. (0.2 CEU)
- Article Number 563718:** Cohen CJ. Successful HIV Treatment: Lessons Learned. (*IDIS* Note: The 2.0 Hours of CE Credit is For All Articles in the Issue, Article Numbers 563717-563719). *J Manag Care Pharm* 2006, 12:S6-S11. (0.2 CEU)
- Article Number 563717:** Chao SH. The HIV Landscape in a Managed Care Environment: Current Challenges and Potential Solutions. (*IDIS* Note: The 2.0 Hours of CE Credit is For All Articles in the Issue, Article Numbers 563717-563719). *J Manag Care Pharm* 2006, 12: S2-S5. (0.2 CEU)
- Article Number 563184:** Martina SD, Ismail MS, Vesta KS. Cilomilast: Orally Active Selective Phosphodiesterase-4 Inhibitor for Treatment of Chronic Obstructive Pulmonary Disease. *Ann Pharmacotherapy* 2006, 40:1822-1828. (0.1 CEU)
- Article Number 563183:** Brousil JA, Roberts RJ, Schlein AL. Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis. *Ann Pharmacotherapy* 2006, 40:1814-1821. (0.1 CEU)
- Article Number 563180:** Cheng JWM. Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events. *Ann Pharmacotherapy* 2006, 1785-1796. (0.1 CEU)
- Article Number 563179:** Yoo BK, Triller DM, Yoo DJ. Exenatide: A New Option for the Treatment of Type 2 Diabetes. *Ann Pharmacotherapy* 2006, 40:1777-1784. (0.1 CEU)

FDA Advisory Committee Meetings

Article Numbers 564054-564059: Nonprescription Drugs FDA Advisory Committee Meeting, October 20-21, 2005. *FDA Advisory Committee* 2005.

Article Numbers 564047-564053: Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee. January 13-14, 2005. *FDA Advisory Committee* 2005.

Article Numbers 564041-564046: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, September 9, 2005. *FDA Advisory Committee* 2005.

Article Numbers 564038-564040: Joint Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee, March 24, 2005. *FDA Advisory Committee* 2005.

Article Numbers 564036-564037: Anesthetic and Life Support Drugs Advisory Committee Meeting, November 10, 2005. *FDA Advisory Committee* 2005.